{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:57:09Z","timestamp":1773925029196,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T00:00:00Z","timestamp":1533600000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Palliat Care"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12904-018-0348-7","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T16:01:06Z","timestamp":1533657666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Trends in treatment during the last stages of life in end-stage gynecologic cancer patients who received active palliative chemotherapy: a comparative analysis of 10-year data in a single institution"],"prefix":"10.1186","volume":"17","author":[{"given":"Tae-Kyu","family":"Jang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Wha","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Yeol","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Shik","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Hyeok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Man","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Tak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,7]]},"reference":[{"key":"348_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1200\/JCO.2004.08.136","volume":"22","author":"CC Earle","year":"2004","unstructured":"Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004;22:315\u201321.","journal-title":"J Clin Oncol"},{"key":"348_CR2","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S1470-2045(12)70588-0","volume":"14","author":"K Senior","year":"2013","unstructured":"Senior K. Homing in on new cancer drug targets? Lancet Oncol. 2013;14:e49.","journal-title":"Lancet Oncol"},{"key":"348_CR3","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.2174\/138161212802002814","volume":"18","author":"BJ Monk","year":"2012","unstructured":"Monk BJ, Dalton H, Benjamin I, Tanovic A. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer. Curr Pharm Des. 2012;18:3754\u201369.","journal-title":"Curr Pharm Des"},{"key":"348_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.7326\/0003-4819-134-12-200106190-00009","volume":"134","author":"EB Lamont","year":"2001","unstructured":"Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med. 2001;134:1096\u2013105.","journal-title":"Ann Intern Med"},{"key":"348_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s005200000163","volume":"8","author":"R Sapir","year":"2000","unstructured":"Sapir R, Catane R, Kaufman B, Isacson R, Segal A, Wein S, et al. Cancer patient expectations of and communication with oncologists and oncology nurses: the experience of an integrated oncology and palliative care service. Support Care Cancer. 2000;8:458\u201363.","journal-title":"Support Care Cancer"},{"key":"348_CR6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/082585979701300305","volume":"13","author":"A Chan","year":"1997","unstructured":"Chan A, Woodruff RK. Communicating with patients with advanced cancer. J Palliat Care. 1997;13:29\u201333.","journal-title":"J Palliat Care"},{"key":"348_CR7","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3109\/0284186X.2011.653440","volume":"51","author":"TW Liu","year":"2012","unstructured":"Liu TW, Chang WC, Wang HM, Chen JS, Koong SL, Hsiao SC, et al. Use of chemotherapy at the end of life among Taiwanese cancer decedents, 2001-2006. Acta Oncol. 2012;51:505\u201311.","journal-title":"Acta Oncol"},{"key":"348_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.7326\/0003-4819-138-8-200304150-00011","volume":"138","author":"EJ Emanuel","year":"2003","unstructured":"Emanuel EJ, Young-Xu Y, Levinsky NG, Gazelle G, Saynina O, Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003;138:639\u201343.","journal-title":"Ann Intern Med"},{"key":"348_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1634\/theoncologist.11-10-1095","volume":"11","author":"JR Murillo Jr","year":"2006","unstructured":"Murillo JR Jr, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist. 2006;11:1095\u20139.","journal-title":"Oncologist"},{"key":"348_CR10","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/00005650-200005000-00009","volume":"38","author":"NA Christakis","year":"2000","unstructured":"Christakis NA, Iwashyna TJ. Impact of individual and market factors on the timing of initiation of hospice terminal care. Med Care. 2000;38:528\u201341.","journal-title":"Med Care"},{"key":"348_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/jjco\/hyn031","volume":"38","author":"B Keam","year":"2008","unstructured":"Keam B, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, et al. Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol. 2008;38:381\u20136.","journal-title":"Jpn J Clin Oncol"},{"key":"348_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.ygyno.2017.02.027","volume":"145","author":"KL Ring","year":"2017","unstructured":"Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, Jazaeri AA. Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol. 2017;145:462\u20138.","journal-title":"Gynecol Oncol"},{"key":"348_CR13","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.3802\/jgo.2017.28.e20","volume":"28","author":"V Heong","year":"2017","unstructured":"Heong V, Ngoi N, Tan DS. Update on immune checkpoint inhibitors in gynecological cancers. J Gynecol Oncol. 2017;28:e20.","journal-title":"J Gynecol Oncol"},{"key":"348_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s12094-012-0847-6","volume":"14","author":"J Sanz Ortiz","year":"2012","unstructured":"Sanz Ortiz J. Chemotherapy at the end of life: up until when? Clin Transl Oncol. 2012;14:667\u201374.","journal-title":"Clin Transl Oncol"},{"key":"348_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1472-684X-13-51","volume":"13","author":"S Sezgin Goksu","year":"2014","unstructured":"Sezgin Goksu S, Gunduz S, Unal D, Uysal M, Arslan D, Tatli AM, et al. Use of chemotherapy at the end of life in Turkey. BMC Palliat Care. 2014;13:51.","journal-title":"BMC Palliat Care"},{"key":"348_CR16","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/annonc\/mdp027","volume":"20","author":"S Kao","year":"2009","unstructured":"Kao S, Shafiq J, Vardy J, Adams D. Use of chemotherapy at end of life in oncology patients. Ann Oncol. 2009;20:1555\u20139.","journal-title":"Ann Oncol"},{"key":"348_CR17","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00520-015-2959-3","volume":"24","author":"T Assi","year":"2016","unstructured":"Assi T, El Rassy E, Tabchi S, Ibrahim T, Moussa T, Chebib R, et al. Treatment of cancer patients in their last month of life: aimless chemotherapy. Support Care Cancer. 2016;24:1603\u20138.","journal-title":"Support Care Cancer"},{"key":"348_CR18","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1002\/cncr.20207","volume":"100","author":"M Theodoulou","year":"2004","unstructured":"Theodoulou M, Hudis C. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer. 2004;100:2052\u201363.","journal-title":"Cancer"},{"key":"348_CR19","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811\u20138.","journal-title":"J Clin Oncol"},{"key":"348_CR20","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/IGC.0b013e3181b62f38","volume":"19","author":"G Seliger","year":"2009","unstructured":"Seliger G, Mueller LP, Kegel T, Kantelhardt EJ, Grothey A, Groe R, et al. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:1446\u201353.","journal-title":"Int J Gynecol Cancer"},{"key":"348_CR21","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2007;25:5165\u201371.","journal-title":"J Clin Oncol"},{"key":"348_CR22","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","volume":"25","author":"SA Cannistra","year":"2007","unstructured":"Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180\u20136.","journal-title":"J Clin Oncol"},{"key":"348_CR23","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1002\/cncr.25967","volume":"117","author":"KF McGonigle","year":"2011","unstructured":"McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer. 2011;117:3731\u201340.","journal-title":"Cancer"},{"key":"348_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret hospital phase II consortia. J Clin Oncol. 2008;26:76\u201382.","journal-title":"J Clin Oncol"},{"key":"348_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cell.2017.03.034","volume":"169","author":"KY Lin","year":"2017","unstructured":"Lin KY, Kraus WL. PARP inhibitors for cancer therapy. Cell. 2017;169:183.","journal-title":"Cell"},{"key":"348_CR26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2015;33:244\u201350.","journal-title":"J Clin Oncol"},{"key":"348_CR27","doi-asserted-by":"crossref","unstructured":"Wright AA, Zhang BH, Ray A, Mack JW, Trice E, Balboni T, et al. Associations between end-of-life discussions, patient mental health, medical care near death and caregiver bereavement adjustment, Jama-J Am Med Assoc 2008;300:1665\u20131673.","DOI":"10.1001\/jama.300.14.1665"},{"key":"348_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00520-014-2444-4","volume":"23","author":"YJ Lee","year":"2015","unstructured":"Lee YJ, Yang JH, Lee JW, Yoon J, Nah JR, Choi WS, et al. Association between the duration of palliative care service and survival in terminal cancer patients. Support Care Cancer. 2015;23:1057\u201362.","journal-title":"Support Care Cancer"},{"key":"348_CR29","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdq778","volume":"22","author":"U Nappa","year":"2011","unstructured":"Nappa U, Lindqvist O, Rasmussen BH, Axelsson B. Palliative chemotherapy during the last month of life. Ann Oncol. 2011;22:2375\u201380.","journal-title":"Ann Oncol"},{"key":"348_CR30","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.29485","volume":"121","author":"MC Cheung","year":"2015","unstructured":"Cheung MC, Earle CC, Rangrej J, Ho TH, Liu N, Barbera L, et al. Impact of aggressive management and palliative care on cancer costs in the final month of life. Cancer. 2015;121:3307\u201315.","journal-title":"Cancer"},{"key":"348_CR31","doi-asserted-by":"publisher","first-page":"75s","DOI":"10.1200\/JOP.2011.000469","volume":"8","author":"B Chastek","year":"2012","unstructured":"Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8:75s\u201380s.","journal-title":"J Oncol Pract"}],"container-title":["BMC Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-018-0348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12904-018-0348-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-018-0348-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T23:07:35Z","timestamp":1565132855000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpalliatcare.biomedcentral.com\/articles\/10.1186\/s12904-018-0348-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["348"],"URL":"https:\/\/doi.org\/10.1186\/s12904-018-0348-7","relation":{},"ISSN":["1472-684X"],"issn-type":[{"value":"1472-684X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,7]]},"assertion":[{"value":"6 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board (IRB) of Asan Medical Center in Korea and is specified in our manuscript. (IRB approval No. 2017\u20130832) Patient information was coded and anonymized. In addition, due to the retrospective nature of our study and the use of data from patients who had already died, patient consent was not necessary.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"99"}}